Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | LGMN | Q99538 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14327688 | 0.87 | KIF11 (0.38) | CYP2C19KCNH2KIF11LGMN | |
| SCHEMBL25557807 | 0.83 | TSHR (0.41) | PDGFRBPDGFRAKIF11LGMN | |
| SCHEMBL4729458 | 0.83 | TRPV4 (0.37) | SQORGRM5PTGS2CYP3A4CYP2C9 | |
| SCHEMBL24593921 | 0.82 | CYP3A4 (0.39) | GPR55PDGFRBPDGFRAGRM5PTGS2 | |
| SCHEMBL14062425 | 0.82 | KIF11 (0.53) | KIF11 | |
| SCHEMBL10220397 | 0.82 | NPC1 (0.45) | KCNH2KIF11LGMN | |
| SCHEMBL12173602 | 0.82 | KIF11 (0.53) | KIF11 | |
| SCHEMBL25658846 | 0.80 | CYP11B2 (0.43) | GPR55LGMN | |
| SCHEMBL22601471 | 0.80 | KIF11 (0.55) | PDGFRBPDGFRACYP3A4KIF11 | |
| SCHEMBL4790086 | 0.76 | SOS1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | PYGM, TNNC1, MUSK | GPR55 3581/4885PDGFRB 2967/4885PDGFRA 3118/4885 |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | GPR55 3742/4885PDGFRB 4116/4885PDGFRA 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.